A metered-dose inhaler that took eight years to develop is now being distributed across Australia by Novachem, with the technology's creator claiming it will "revolutionise" how medicinal cannabis is delivered to patients.
The device, known as SyqeAir, was created by Israeli medtech company Syqe Medical.
Novachem has taken on the role of Australian distributor for the product, which is now accessible through the Special Access Scheme.
SyqeAir had previously been introduced to a limited number of patients in the local market through Melbourne-based eCS Clinic, which operates under Kensana Health.
The inhaler will use cannabis cultivated by Dutch producer Bedrocan. Prescriptions will come with pre-loaded cartridges containing 60 doses each, available in increments of 250mg of THC, up to a maximum of 1,000mg.
SyqeAir chief executive Hagit Kamin said: "The inhaler will allow patients in Australia to benefit from our groundbreaking technology through rapid, metered, consistent and precise cannabis treatment.
"The inhaler is also supported by published clinical studies and real-world evidence demonstrating its short and long-term effectiveness and safety."
The company argued that vaporisers currently on the market lack the same depth of clinical data and cannot deliver the consistent dosing that the Syqe product offers.
The device does not come at a low price, however, with sources indicating it will cost patients A$880.
Novachem is hoping health insurers will find the technology compelling enough to provide at least partial cover for the inhaler. The company is also optimistic that the Department of Veterans' Affairs may be willing to subsidise the cost.
Novachem business development manager Andrew Heath said the inhaler will offer a distinct advantage over the "suck and hope" vaporisers on the market.
The inhaler's precise dosing mechanism may also appeal to doctors who have previously been reluctant to prescribe medicinal cannabis, he said.
